Skip to content

Author

J. Goldberg

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Phase II study of pembrolizumab plus nab-paclitaxel in Hormone Receptor–positive, HER2- negative metastatic breast cancer: clinical and molecular insights into response

Abstract Purpose We investigate the addition of PD-1 blockade to chemotherapy in HR + MBC to assess efficacy, safety, and changes in the tumor microenvironment utilizing serial tumor biopsies. Methods Single-arm phase 2 clinical trial (NCT02752685) of 20 HR+/HER2- MBC patients received nab-paclitaxel (100mg/m2 IV d1/8,...

N. Klar, J. Goldberg, Apoorvi Tyagi et al. · 0 citations
Open access Oct 2026

Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first-line therapy

Background Treatment options for refractory gastric cancer are limited. Preclinical data suggest interplay between angiogenesis and immune regulation, with vascular endothelial growth factor impairing antitumor immunity through decreasing antigen presentation, effector function, and immune cell trafficking. This phase...

J. Lee, P. Oberstein, J. Goldberg et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.